Session » Systemic Sclerosis and Related Disorders – Clinical Poster II

Date: Monday, October 22, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1730

A Role for Duplex Ultrasound of Hand Arteries in the Assessment of the Vasculopathy Associated to Systemic Sclerosis-like Diseases

9:00AM-11:00AM: Abstract Number: 1732

Alterations of Body Composition in Patients with Systemic Scleroderma Are Associated with Disease Activity, Physical Activity and Serum Levels of Inflammatory Cytokines

9:00AM-11:00AM: Abstract Number: 1734

Association of Short-Term Longitudinal Changes in Clinical and Physiologic Variables with Overall Survival in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

9:00AM-11:00AM: Abstract Number: 1738

Detect Outperforms Echocardiography Based Screening Guidelines for Early Detection of Systemic Sclerosis Associated Pulmonary Arterial Hypertension

9:00AM-11:00AM: Abstract Number: 1735

Diagnostic Accuracy of MR Angiography in a Cohort with Systemic Sclerosis Compared to Other Rheumatic Diseases with Acral Hypoperfusion

9:00AM-11:00AM: Abstract Number: 1741

Disease Duration and Autoantibodies Predict Distinct Skin Score Trajectories in Diffuse Cutaneous Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1742

Disease-Specific Autoantibodies Associate with Remarkably Different Risk of Development of Significant Lung Fibrosis in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1724

Effectiveness and Safety of Rituximab for the Treatment of Refractory Systemic Sclerosis Associated Calcinosis: A Case Series

9:00AM-11:00AM: Abstract Number: 1740

Effectiveness and Safety of Tocilizumab for the Treatment of Refractory Systemic Sclerosis Associated Interstitial Lung Disease: A Case Series

9:00AM-11:00AM: Abstract Number: 1716

Evaluation of American College of Rheumatology Provisional Composite Response Index in Systemic Sclerosis in a Phase II Trial of Abatacept Vs. Placebo

9:00AM-11:00AM: Abstract Number: 1717

Expert Consensus on the Screening, Treatment, and Management of Patients with Systemic Sclerosis-Interstitial Lung Disease, and the Potential Role of Anti-Fibrotics in a Treatment Paradigm for Systemic Sclerosis-Interstitial Lung Disease: A Delphi Consensus Study

9:00AM-11:00AM: Abstract Number: 1725

Fecal Microbiota Transplantation in Patients with Systemic Sclerosis- a Pilot Study

9:00AM-11:00AM: Abstract Number: 1719

High-Throughput Quantitative Histology in Systemic Sclerosis Skin Disease Using Computer Vision

9:00AM-11:00AM: Abstract Number: 1720

Higher Neutrophil Count Predicts More Severe Skin/Lung Disease and Increased Mortality in Early Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1736

Incidence and Risk Factors for Gangrene in Patients with Systemic Sclerosis from the Eustar Cohort

9:00AM-11:00AM: Abstract Number: 1729

Increased Risk of Valvular Heart Disease in Patients with Systemic Sclerosis: Results from a Population-Based Cohort (1980-2016)

9:00AM-11:00AM: Abstract Number: 1723

Intensified B-Cell Depletion Therapy in Progressive Systemic Sclerosis Patients: 24 Months Follow-up

9:00AM-11:00AM: Abstract Number: 1737

Multiplexed Autoantibody Profiles in a Systemic Sclerosis Clinical Trial Comparing Autologous Hematopoietic Stem Cell Transplantation and Cyclophosphamide

9:00AM-11:00AM: Abstract Number: 1722

Patient-Level Factors Associated with Hospital Readmission Among Patients with Systemic Sclerosis Associated Pulmonary Hypertension

9:00AM-11:00AM: Abstract Number: 1728

Pharmacokinetics of Cyclophosphamide in Scleroderma Treated By Cyclophosphamide Versus Transplantation

9:00AM-11:00AM: Abstract Number: 1744

Prognostic Value of Right Heart Involvement in Systemic Sclerosis:Not Only Pulmonary Arterial Hypertension

9:00AM-11:00AM: Abstract Number: 1727

Prospective Confirmation of Potential Link between Proton Pump Inhibitor Exposure and Calcinosis in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1721

Racial Differences in SSc Disease Presentation: A Cross-Sectional European Scleroderma Trials and Research Group Study

9:00AM-11:00AM: Abstract Number: 1715

Safety and Efficacy of Lenabasum in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects

9:00AM-11:00AM: Abstract Number: 1743

Serum Markers Potentially Associated with PAH in Systemic Sclerosis; A Targeted Screening Approach

9:00AM-11:00AM: Abstract Number: 1726

Sexual Dysfunction in Systemic Sclerosis Female Patients

9:00AM-11:00AM: Abstract Number: 1733

Should We Perform Exercise Echocardiogram As a Screening Test for Pulmonary Arterial Hypertension (PAH) for All Systemic Sclerosis (SSc) Patients?

9:00AM-11:00AM: Abstract Number: 1718

Skin Gene Expression Profiling Predicts Longitudinal Modified Rodnan Skin Score Change

9:00AM-11:00AM: Abstract Number: 1731

Vertebral Fracture Prevalence and Measurement of the Scanographic Bone Attenuation Coefficient on CT-Scan in 70 Patients with Systemic Scleroderma

9:00AM-11:00AM: Abstract Number: 1739

What Do Patient Reported Outcomes for Routine Monitoring of Gastrointestinal Tract Symptoms in a Systemic Sclerosis Center Tell Us about Clinical Features of Potential Small Intestinal Bacterial Overgrowth?

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].